---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013848"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T03:16:22.418491+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q1 revenue down 14% to $149.9M; net loss narrows to $67.6M; signs $225M Labcorp asset sale

## Summary
- Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.
- Signed definitive agreement to sell oncology testing assets to Labcorp for up to $225M ($192.5M at close + $32.5M earnout); expected close H2 2025.
- Board authorized additional $100M for stock buyback (total $200M); ~$40.2M repurchased under prior program since July 2024.
- Post-quarter: exchanged $159.2M convertible notes for 121.4M shares + $63.5M cash.
- Collaboration with Entera Bio for oral GLP-1/glucagon tablet; OPKO purchased 3.7M Entera shares at $2.17/share.

## SEC filing metadata
- accession: 0001437749-25-013848
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774925013848/0001437749-25-013848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774925013848/opk20250417_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013848
- JSON: https://secwatch.observer/filing/0001437749-25-013848.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.